1.Raised plasma concentration and ex vivo production of inflammatory chemokines in patients with systemic lupus erythematosus

Lit, LCW, Wong, CK,     More...

Lit, LCW, Wong, CK, Tam, LS, Li, EKM, Lam, CWK     Less

ANNALS OF THE RHEUMATIC DISEASES[0003-4967], Published 2006, Volume 65, Issue 2, Pages 209-215

收錄情况： WOS SCOPUS

WOS核心合集引用: 145  2022影響因子:  27.4  发表年影響因子:  5.767 

2.Safety and efficacy of leflunomide in the treatment of lupus nephritis refractory or intolerant to traditional immunosuppressive therapy: an open label trial

Tam, LS, Li, EK, Won     More...

Tam, LS, Li, EK, Wong, CK, Lam, CWK, Li, WC, Szeto, CC     Less

ANNALS OF THE RHEUMATIC DISEASES[0003-4967], Published 2006, Volume 65, Issue 3, Pages 417-418

收錄情况： WOS SCOPUS

WOS核心合集引用: 40  2022影響因子:  27.4  发表年影響因子:  5.767 

3.Double blind, randomized, placebo controlled pilot study of leflunomide in systemic lupus erythematosus (SLE)

Tam, LS, Li, EK, Won     More...

Tam, LS, Li, EK, Wong, CK, Lam, CWK, Szeto, CC     Less

ANNALS OF THE RHEUMATIC DISEASES[0003-4967], Published 2004, Volume 63, Pages 213-213

收錄情况： WOS

WOS核心合集引用: 0  2022影響因子:  27.4  发表年影響因子:  3.916